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Purpose: The main purpose of the study was to
determine the safety proﬁle and efﬁcacy of intravenous
ibuprofen administered over 5 to 10 minutes for the
treatment of pain or fever in hospitalized patients.
Current evidence supports the use of intravenous
infusions of ibuprofen to control pain and reduce
the opioid requirements associated with surgical pain.
Current dosing guidelines recommend that the drug be
administered over 30 minutes. However, a more rapid
infusion might yield additional beneﬁts. The safety
proﬁle and efﬁcacy of a shortened infusion time
requires additional study.
Methods: This was a Phase IV multicenter, open-
label, surveillance clinical study. Thirteen clinical
centers located in the United States enrolled a total
of 150 adult hospitalized patients with pain or fever.
Patients experiencing pain received 800 mg intra-
venous ibuprofen infused over 5 to 10 minutes every
6 hours for up to 24 hours (4 doses) and patients
experiencing fever received 400 mg intravenous
ibuprofen infused over 5 to 10 minutes every 4 hours
for up to 24 hours (6 doses). Vital signs, adverse
events, and pain scores were assessed. The exclusion
criteria included inadequate intravenous access;
patients younger than 18 years of age; history of
allergy or hypersensitivity to any component of intra-
venous ibuprofen, aspirin, or other nonsteroid anti-
inﬂammatory drugs; active hemorrhage or clinically
signiﬁcant bleeding; pregnancy or nursing; and pa-
tients in the perioperative period in the setting of
coronary artery bypass graft surgery.360Findings: Adverse events were reported for 43 of
150 patients (29%). The most common adverse events
experienced by patients were infusion site pain in 22
of 150 patients (15%) and ﬂatulence (8 of 150 [5%]).
Four patients (3%) discontinued the study drug due to
infusion-site pain. In the patients experiencing fever,
temperature decreased from baseline over 4 hours
(mean [SD] reduction of 1.5 [1.25]1F). In patients
experiencing pain, patient-reported visual analog scale
scores decreased from baseline over 4 hours (mean
[SD] reduction of 27.1 [31.29] mm).
Implications: The study demonstrates that more
rapid administration of intravenous ibuprofen is well
tolerated and supports intravenous ibuprofen as an
effective treatment for pain and fever in hospitalized
patients. (Clin Ther. 2015;37:360–367) & 2015 The
Authors. Published by Elsevier HS Journals, Inc.
Key words: fever, ibuprofen, intravenous analge-
sics, nonopioid analgesics, nonsterioidal antiinﬂam-
matory drugs, pain.
INTRODUCTION
Pain and fever in the hospital setting are conditions
that require prompt and effective treatment to achieve
and maintain patient comfort.1–3 Patient comfort andVolume 37 Number 2
S.D. Bergese et al.symptom resolution play key roles in the recovery and
healing of hospitalized patients and are therefore
important in determining length of hospital stay.4,5
Oral nonsteroidal antiinﬂammatory drugs (NSAIDs)
have been used for many years to treat pain and fever
in the hospital setting, but a large percentage of these
patients are often unable to take oral medications due
to intubation or unconsciousness.3,6,7 In addition, the
absorption and metabolism of oral drugs in hospi-
talized patients can differ greatly from the nonhospi-
talized population, leading to altered blood levels of
the drug and potential concerns about efﬁcacy and
tolerability.8 These issues can make the intravenous
route a more suitable option for hospitalized patients.
In 2009, the US Food and Drug Administration
approved intravenous ibuprofen for the treatment of
mild to moderate pain, moderate to severe pain as an
adjunct to opioids, and fever. Previous clinical trials of
intravenous ibuprofen administered over 30 minutes
have shown intravenous ibuprofen to be well tolerated
and effective.9–11 However, a shortened infusion time
has the potential to further accelerate the onset of
action of intravenous ibuprofen; achieve higher peak
blood levels, which can potentiate the analgesic,
antipyretic, and anti-inﬂammatory effects; and de-
crease the time burden on the medical staff adminis-
tering the drug.12
Recently, a Phase I study in 12 healthy subjects
examined a 5- to 7-minute infusion time of intra-
venous ibuprofen and found the shortened infusion
time to be well tolerated.13 Subsequently, this Phase
IV multicenter, open-label safety surveillance study
was one of two prospective studies designed to
evaluate the safety proﬁle of a shortened infusion
time. The present study was designed to further
evaluate the safety proﬁle of the rapid 5- to 10-
minute infusion of intravenous ibuprofen in hospital-
ized patients already experiencing pain or fever,
or both.
METHODS
This Phase IV multicenter, open-label, single-dose, and
multiple-dose surveillance clinical study was con-
ducted to assess the safety proﬁle and efﬁcacy of
ibuprofen administered intravenously over 5 to 10
minutes to adult patients with fever (temperature
>1011F) or pain (visual analog scale [VAS] assessment
>3 [30 mm]) in a hospital setting. This study was
approved by site-speciﬁc Institutional Review BoardsFebruary 2015and informed patient consent was obtained from all
patients before study inclusion. Hospitalized patients
experiencing pain and with a baseline VAS assessment
>30 mm or fever with a temperature >1011F were
eligible for enrollment. Exclusion criteria included
patients with inadequate intravenous access; patients
younger than 18 years of age; and those with a history
of allergy or hypersensitivity to any component of
intravenous ibuprofen, aspirin (or aspirin-related
products), or NSAIDs. Additional exclusion criteria
included active hemorrhage or clinically signiﬁcant
bleeding, pregnancy or nursing, and patients in the
perioperative period in the setting of coronary artery
bypass graft surgery. NSAIDs other than study med-
ication were excluded during the treatment and post-
treatment periods.
Eligible patients received one of two dose levels
(400 mg for treatment of fever or 800 mg for treat-
ment of pain) of intravenous ibuprofen. Patients were
permitted to receive up to 5 additional doses of 400
mg (every 4 hours) or 3 additional doses of 800 mg
(every 6 hours) of intravenous ibuprofen, as deter-
mined by the investigator. The drug was diluted in
saline and administered at a concentration ofo4 mg/mL
over 5 to 10 minutes. There was no comparator arm in
this study.
Assessments
To evaluate the tolerability of a single dose of
intravenous ibuprofen administered over 5 to 10
minutes for the treatment of pain or fever, vital signs
were recorded at baseline and 4 hours after ibuprofen
infusion (after the ﬁrst infusion in patients receiving
multiple doses). The incidence of adverse events
occurring within the 6 hours after administration of
intravenous ibuprofen was also assessed. Each site
investigator assessed the association between any
adverse event and intravenous ibuprofen.
To evaluate the tolerability of multiple doses of
intravenous ibuprofen administered over 5 to 10
minutes for the treatment of postoperative pain, the
incidence of adverse events occurring within the 6
hours after administration of the last dose of intra-
venous ibuprofen was collected.
For patients enrolled for the treatment of fever,
temperature assessments were collected frequently
during the subsequent 4 hours after drug infusion.
For patients enrolled for the treatment of pain,
pain intensity was measured frequently during the361
Clinical Therapeuticssubsequent 4 hours after the drug infusion. The pain
intensity was quantiﬁed based on the patient’s self-
assessment using VAS from 0 to 100 mm, with 0 mm
indicating no pain and 100 mm indicating
intense pain.
Statistical Analysis
Formal sample size calculations were not per-
formed. The intent was to enroll 150 patients to
provide descriptive safety proﬁle and efﬁcacy data.
Continuous data were summarized in spreadsheets
listing the mean (SD), median, minimum, and max-
imum. Categorical data were summarized by frequen-
cies and percentages. All data collected during the
study were included in data listings. All data were
listed by treatment group, treatment indication, and
patient. Statistical analyses were conducted with SAS
software, version 9.1.3 or higher (SAS Institute, Cary,
North Carolina).
RESULTS
Thirteen clinical centers in the United States
enrolled patients in this study (Table I). A total of
150 patients were enrolled in the study, with 11
patients enrolled for the treatment of fever and 139
enrolled for the treatment of pain (fever n ¼ 11;
pain n ¼ 139). Demographic and baseline char-
acteristics are presented in Table II. Baseline pain
was divided into two categories: mild to moderateTable I. List of investigators and institutions participatin
Investigator Inst
Sabry Ayad, MD Cleveland Clinic
Sergio D. Bergese, MD Ohio State University
Richard L. Boortz-Marx MD University of North C
Keith A. Candiotti, MD University of Miami H
Dmitri Chamchad, MD Lankenau Medical Ce
Damanjeet Chaubey, MD Danbury Hospital
Tong J. Gan, MD Duke University Medi
Stephen A Mayer, MD Columbia University M
Peter E. Morris, MD Wake Forest Universit
Nathan Shapiro, MD Beth-Israel Deaconess
Gary Vercruysse, MD Grady Health
Gary M. Vilke, MD University of Californ
Patrick E. Wright Jr, MD Moses Cone Hospita
362(VAS o30 to r65 mm) and moderate to severe
(VAS 65 tor100 mm). Of the 150 patients enrolled
in the study, 97 patients (65%) received a single
dose of intravenous ibuprofen and 53 patients
(35%) received multiple doses (2 or more) (Table III).
Of the 139 patients enrolled for the treatment of
pain, 79 patients (57%) were treated for post-
operative pain and 60 patients (43%) were treated
for nonsurgical pain (Table IV).
Vital signs were measured at baseline and 1 hour
post dose of intravenous ibuprofen. No signiﬁcant
differences were observed from baseline and 1 hour
post dose for any vital sign other than temperature
(Table V). Adverse events were reported for 43 of
the 150 patients (29%). For the 43 patients
experiencing adverse events, most patients
experienced adverse events that were mild to
moderate in intensity (40 of 43 patients [93%];
Table VI). The most common adverse event
experienced by patients was infusion site pain or
discomfort (24 of 150 patients [16%]). Other
adverse events reported by >3% of patients
included ﬂatulence, nausea, abnormal breath
sounds, and hyperglycemia (Table VII). Four (3%)
patients discontinued the study drug due to
infusion-site pain. One serious adverse event was
reported, a case of hypotension that was deemed
unrelated to intravenous ibuprofen in the investiga-
tor’s assessment of the relationship (Table VI).g in this multicenter study.
itution Location
Cleveland, OH
Medical Center Columbus, OH
arolina Health System Chapel Hill, NC
ealth System Miami, FL
nter Wynnewood, PA
Danbury, CT
cal Center Durham, NC
edical Center New York, NY
y Baptist Medical Center Winston-Salem, NC
Medical Center Boston, MA
Atlanta, GA
ia at San Diego San Diego, CA
l Greensboro, NC
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Table II. Demographic and baseline characteristics of the patients enrolled in the study. Data are given as
n (%) unless otherwise noted.
Demographics
Fever, 400 mg Ibuprofen
(n ¼ 11)
Pain, 800 mg Ibuprofen
(n ¼ 139)
Total
(n ¼ 150)
Age, y, mean (SD) 55 (18.9) 48 (14.8) 49 (15.1)
Weight, kg, mean (SD) 90.5 (17.1) 87.4 (28.6) 87.6 (27.9)
Sex
Male 5 (45) 54 (39) 59 (39)
Female 6 (55) 85 (61) 91 (61)
Race
European American 5 (45) 101 (73) 106 (71)
African American 2 (18) 32 (23) 34 (23)
Asian American 1 (9) 2 (1) 3 (2)
Other 3 (27) 4 (3) 7 (5)
Ethnicity
Hispanic or Latino 3 (27) 7 (5) 10 (7)
Not Hispanic or Latino 8 (73) 132 (95) 140 (93)
Baseline pain intensity*
Mild to moderate (VAS 30 to r65 mm) NA 78 (57) 78 (52)
Moderate to severe (VAS 65 to 100 mm) NA 58 (43) 58 (39)
NA ¼ not available; VAS ¼ visual analog scale.
*Three patients did not have a baseline pain intensity assessment.
S.D. Bergese et al.Temperature assessments over the 4 hours after a
dose of intravenous ibuprofen were collected for those
enrolled for treatment of fever. A decrease in temper-
ature was observed over time with a mean (SD)
decrease of 1.5 (1.25)1F after 4 hours (Figure 1).Table III. Extent of exposure to intravenous ibuprofen. D
No. of Doses
Fever, 400 mg Ibuprofen
(n ¼ 11)
Single 1 (9)
Multiple doses 10 (91)
2 doses 0
3 doses 2 (18)
4 doses 1 (9)
5 doses 3 (27)
6 doses 4 (36)
NA ¼ not available.
February 2015Similarly, in patients receiving intravenous ibuprofen
for management of pain, a decrease in patient-
reported VAS (0100 mm) scores was observed over
the 6 hours after a dose of intravenous ibuprofen,
with up to a 52% decrease from the baseline pain levelata are given as n (%).
Pain, 800 mg Ibuprofen
(n ¼ 139)
Total
(n ¼ 150)
96 (69) 97 (65)
43 (31) 53 (35)
6 (4) 6 (4)
7 (5) 9 (6)
30 (22) 31 (21)
NA 3 (2)
NA 4 (3)
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Table IV. Summary of pain etiology. Data are
given as n (%).
Pain
Pain, 800 mg Ibuprofen
(n ¼ 139)
Postoperative pain 79 (57)
Nonsurgical pain 60 (43)
Abdominal pain 12 (9)
Back pain 7 (5)
Burn pain 7 (5)
Post-traumatic pain 4 (3)
Painful respiration 5 (4)
Pain in extremity 4 (3)
Chest pain 3 (2)
Groin pain 2 (1)
General pain 2 (1)
Musculoskeletal pain 2 (1)
Pain of skin 2 (1)
Uterine pain 2 (1)
Bone pain 1 (o1)
Cervical root pain 1 (o1)
Gallbladder pain 1 (o1)
Oropharyngeal pain 1 (o1)
Pelvic pain 1 (o1)
Renal pain 1 (o1)
Urethral pain 1 (o1)
Headache 1 (o1)
Table V. Vital signs at baseline and 1 hour after the init
as mean (SD).
Vital Signs
Fever, 400 mg Ibu
(n ¼ 11)
Pulse rate, beats/min
Baseline 90 (13.2)
Hour 1 87 (15.7)
Respiratory rate, breaths/min
Baseline 21 (4.4)
Hour 1 20 (5.3)
Systolic blood pressure, mm Hg
Baseline 145 (24.1)
Hour 1 137 (25.6)
Diastolic blood pressure, mm Hg
Baseline 70 (13.2)
Hour 1 66 (13.3)
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364(Table VIII, Figure 2). The decrease in pain scores
appeared to be more pronounced in those patients
presenting with moderate to severe pain at baseline
compared with those presenting with mild to
moderate pain (Figure 2); however, concomitant
medications were not controlled, which did not
allow for deﬁnitive conclusions.DISCUSSION
The present study was one of two trials designed to
assess the safety proﬁle of a more rapid 5- to 10-
minute infusion time of intravenous ibuprofen. The
study population included a wide range of patient
groups and clinical diagnoses, including both surgical
and nonsurgical patients. Such diversity created the
possibility of inﬂuence of several confounding factors
on the study results, for example, use of opioids or
other analgesics. However, such an approach allowed
for assessing the tolerability and efﬁcacy of the new
mode of drug administration in patient categories
representative of a typical major hospital. In this
study, adverse events were reported in 43 of the 150
patients, with infusion-site pain (24 of 150 patients
[16%]) as the most common adverse event. The
infusion-site pain safety proﬁle results from this study
are consistent with other intravenous analgesic infu-
sion pain safety proﬁle data. Previous studies have
demonstrated a range of 5% to 29%14–16 incidence ofial infusion of intravenous ibuprofen. Data are given
profen Pain, 800 mg Ibuprofen
(n ¼ 139)
Total
(n ¼ 150)
80 (18.1) 81 (17.9)
79 (17.4) 80 (17.3)
17 (3.4) 17 (3.7)
17 (3.1) 18 (3.4)
128 (19.0) 129 (19.8)
124 (17.8) 125 (18.7)
74 (13.8) 74 (13.7)
71 (12.3) 70 (12.4)
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Table VI. Number of patients experiencing adverse
events. Data are given as n (%).
Adverse Events
Fever, 400 mg
Ibuprofen
(n ¼ 11)
Pain, 800 mg
Ibuprofen
(n ¼ 139)
Total
(n ¼ 150)
Any adverse event 0 43 (31) 43 (29)
Mild 0 19 (14) 19 (13)
Moderate 0 21 (15) 21 (14)
Severe 0 3 (2) 3 (2)
Any serious
adverse event
0 1 (o1) 1 (o1)
S.D. Bergese et al.infusion-site pain. Another injectable NSAID, ketor-
olac, reported injection-site pain ranging from 19% to
29%.14
In patients receiving intravenous ibuprofen for
management of pain, patient-reported mean VAS
scores decreased from baseline for all time points.
A mean VAS score reduction of 29% was observed
from baseline to 15 minutes post dose, and up to a
52% decrease from the baseline pain level was
registered during the 6-hour follow-up period. Pre-
vious studies have shown up to a 32% reduction of
integrated VAS assessed at rest with use of a 30-
minute infusion of intravenous ibuprofen.9 Our
study adds to the existing data and indicates that a
shortened infusion time of intravenous ibuprofen can
be a well tolerated and effective alternative, and yield
additional beneﬁts, such as reduced work burden and
faster onset of drug action. This shortened infusion
time of intravenous ibuprofen has the potential to
achieve higher peak blood levels of intravenousTable VII. Adverse events occurring in Z3% of
patients. Data are given as n (%).
Adverse Events
Total
(n ¼ 150)
Infusion-site reaction
(pain or discomfort)
24 (16)
Flatulence 8 (5)
Nausea 4 (3)
Breath sounds abnormal 4 (3)
Hyperglycemia 4 (3)
February 2015ibuprofen at a more rapid pace, which can
potentiate the analgesic, antipyretic, and anti-
inﬂammatory effects, and maximize the onset of
action. Previous studies have reported on the safety
proﬁle and efﬁcacy of shortened infusion time of
intravenous ibuprofen.9,13 It was established that the
Tmax of intravenous ibuprofen administered within
5 to 7 minutes equals 0.11 hour.13 Obviously,
the faster drug administration and resulting
faster onset of action (as determined during the
drug development phase by Cumberland Pharma-
ceuticals, Inc.) decreases the time burden on the
medical staff administering the drug and improves
the quality of patient care. Urgent pain relief is a
necessity in optimizing patient comfort and impro-
ving patient outcome and, therefore, onset of action
plays a critical role in treating numerous types of
existing pain seen throughout the hospital, such as
postsurgical pain, fractures, and neuropathic pain.4,5
In addition, the advent of a rapid infusion of intra-
venous ibuprofen could provide more timely and
robust fever reduction in critically ill patients with a
high fever. We think that, in addition to providing
additional tolerability and efﬁcacy data supporting
the shortened infusion time of intravenous ibuprofen,
it would be desirable to design a study to compare
the drug kinetics, pharmacodynamic effects, and
incidence of treatment-related adverse effects of
5- to 7-minute infusion with the conventional
30-minute infusion of intravenous ibuprofen.102.5
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Figure 1. Summary of temperature over time,
n ¼ 11 (mean [SEM]).
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Table VIII. Summary of changes in visual analog scale scores over time. Data are given as mean (SD) unless
otherwise noted.
Time Point
VAS Score (0100 mm)
(n ¼ 139)
Change in Pain,
800 mg
Decrease from
Baseline, %
Baseline (dose 1) 61.4 (23.11) NA
15 Minutes post dose 43.9 (26.21) 17.2 (24.04) 29
30 Minutes post dose 36.6 (26.13) 24.5 (26.38) 40
1 Hour post dose 30.5 (26.35) 31.0 (29.45) 50
2 Hours post dose 30.9 (23.90) 31.8 (30.56) 52
3 Hours post dose 32.2 (24.34) 30.3 (29.11) 50
4 Hours post dose 35.9 (27.95) 27.1 (31.29) 44
NA ¼ not available; VAS ¼ visual analog scale.
Clinical TherapeuticsThis study had several limitations. First, as an open-
label, single treatment-arm study, there was no control
arm. The use of additional analgesics and antipyretics
other than the study drug was permitted before the
treatment period, allowing for the potential of adverse
effects and efﬁcacy results not associated with intra-
venous ibuprofen. Another source of variability was the
wide range of pain types and differences in ibuprofen
efﬁcacy in treating the pain of different etiologies.100
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Figure 2. Summary of pain intensity over time, n ¼ 139
366CONCLUSIONS
The results of this trial add to a growing body of
literature that supports the tolerability and efﬁcacy of
a 5- to 10-minute infusion of intravenous ibuprofen.
This study also supports the utility of intravenous
ibuprofen in the management of various types of pain,
including surgical and nonsurgical. A shortened in-
fusion can aid in aggressive fever control in the acute
emergency department and critical care setting. Thisity over Time
All patients
Mild to moderate baseline pain
Moderate to server baseline pain
20
inutes)
180 240
(mean [SEM]).
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S.D. Bergese et al.study suggests that hospital protocols for pain, inﬂam-
mation, and fever management could effectively adopt
a shortened infusion time of intravenous ibuprofen.
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